CN Patent

CN119403808A — 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂

Assigned to Due To Siklix Biotechnology Co ltd · Expires 2025-02-07 · 1y expired

What this patent protects

使用本文描述的以下结构的基于嘧啶的选择性细胞周期蛋白依赖性激酶2(CDK2)：(化合物I)，或其药学上可接受的盐或形态学形式，用于治疗以具有扩增的细胞周期蛋白E活化和/或表达的异常细胞分裂或异常细胞分裂障碍、CDK4/6抵抗性和/或内分泌疗法抵抗性为特征的障碍，包括但不限于治疗肿瘤和癌症。

USPTO Abstract

使用本文描述的以下结构的基于嘧啶的选择性细胞周期蛋白依赖性激酶2(CDK2)：(化合物I)，或其药学上可接受的盐或形态学形式，用于治疗以具有扩增的细胞周期蛋白E活化和/或表达的异常细胞分裂或异常细胞分裂障碍、CDK4/6抵抗性和/或内分泌疗法抵抗性为特征的障碍，包括但不限于治疗肿瘤和癌症。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN119403808A
Jurisdiction: CN
Classification: —
Expires: 2025-02-07
Drug substance claim: No
Drug product claim: No
Assignee: Due To Siklix Biotechnology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.